Mean weight loss was 1.5% to 3.2% at day 29. The cash-strapped biotech says the drug is easier on the gut and wants a partner to run phase 2.
Recap by typeshit. Full story at Fierce Biotech.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
Bariatric surgeon Sergey Terushkin covers the heart, kidney, sleep apnea and liver approvals, plus uses like alcohol use disorder that are still being studied.
A brief pointer to information on nausea, a common side effect of GLP-1 drugs. The post itself offers no further detail.
Loading…